Literature DB >> 21673857

Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries.

Alexandra Cameron, Ilse Roubos, Margaret Ewen, Aukje K Mantel-Teeuwisse, Hubertus G M Leufkens, Richard O Laing.   

Abstract

OBJECTIVE: To investigate potential differences in the availability of medicines for chronic and acute conditions in low- and middle-income countries.
METHODS: Data on the availability of 30 commonly-surveyed medicines - 15 for acute and 15 for chronic conditions - were obtained from facility-based surveys conducted in 40 developing countries. Results were aggregated by World Bank country income group and World Health Organization region.
FINDINGS: The availability of medicines for both acute and chronic conditions was suboptimal across countries, particularly in the public sector. Generic medicines for chronic conditions were significantly less available than generic medicines for acute conditions in both the public sector (36.0% availability versus 53.5%; P = 0.001) and the private sector (54.7% versus 66.2%; P = 0.007). Antiasthmatics, antiepileptics and antidepressants, followed by antihypertensives, were the drivers of the observed differences. An inverse association was found between country income level and the availability gap between groups of medicines, particularly in the public sector. In low- and lower-middle income countries, drugs for acute conditions were 33.9% and 12.9% more available, respectively, in the public sector than medicines for chronic conditions. Differences in availability were smaller in the private sector than in the public sector in all country income groups.
CONCLUSION: Current disease patterns do not explain the significant gaps observed in the availability of medicines for chronic and acute conditions. Measures are needed to better respond to the epidemiological transition towards chronic conditions in developing countries alongside current efforts to scale up treatment for communicable diseases.

Mesh:

Substances:

Year:  2011        PMID: 21673857      PMCID: PMC3099556          DOI: 10.2471/BLT.10.084327

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  17 in total

1.  The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.

Authors:  Shanti Mendis; Keiko Fukino; Alexandra Cameron; Richard Laing; Anthonio Filipe; Oussama Khatib; Jerzy Leowski; Margaret Ewen
Journal:  Bull World Health Organ       Date:  2007-04       Impact factor: 9.408

2.  AEDs availability and professional practices in delivery outlets in a city center in southern Vietnam.

Authors:  Tu Luong Mac; Van Tuan Le; Anh Nhi Vu; Pierre-Marie Preux; Voa Ratsimbazafy
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

3.  Insights for policymakers from a medicine price survey in Rajasthan.

Authors:  Anita Kotwani; Nirmal Gurbani; Sangeeta Sharma; R R Chaudhury
Journal:  Indian J Med Res       Date:  2009-04       Impact factor: 2.375

Review 4.  Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.

Authors:  Edward J Mills; Jean B Nachega; Iain Buchan; James Orbinski; Amir Attaran; Sonal Singh; Beth Rachlis; Ping Wu; Curtis Cooper; Lehana Thabane; Kumanan Wilson; Gordon H Guyatt; David R Bangsberg
Journal:  JAMA       Date:  2006-08-09       Impact factor: 56.272

Review 5.  Preventing chronic diseases: how many lives can we save?

Authors:  Kathleen Strong; Colin Mathers; Stephen Leeder; Robert Beaglehole
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

6.  A randomized controlled trial of an asthma clinical pathway for children in general practice.

Authors:  E A Mitchell; P B Didsbury; N Kruithof; E Robinson; M Milmine; M Barry; J Newman
Journal:  Acta Paediatr       Date:  2005-02       Impact factor: 2.299

Review 7.  Metformin monotherapy for type 2 diabetes mellitus.

Authors:  A Saenz; I Fernandez-Esteban; A Mataix; M Ausejo; M Roque; D Moher
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

8.  Household catastrophic health expenditure: a multicountry analysis.

Authors:  Ke Xu; David B Evans; Kei Kawabata; Riadh Zeramdini; Jan Klavus; Christopher J L Murray
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.

Authors:  Zaheer Ud Din Babar; Mohamed Izham Mohamed Ibrahim; Harpal Singh; Nadeem Irfan Bukahri; Andrew Creese
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

View more
  59 in total

1.  Decision dilemmas: worse in emerging economies.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

2.  Mapping actions to improve access to medicines for mental disorders in low and middle income countries.

Authors:  C Barbui; T Dua; K Kolappa; B Saraceno; S Saxena
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-09       Impact factor: 6.892

3.  Private sector contributions and their effect on physician emigration in the developing world.

Authors:  Lawrence C Loh; Cesar Ugarte-Gil; Kwame Darko
Journal:  Bull World Health Organ       Date:  2013-01-17       Impact factor: 9.408

4.  Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries.

Authors:  Catherine E Vialle-Valentin; Brian Serumaga; Anita K Wagner; Dennis Ross-Degnan
Journal:  Health Policy Plan       Date:  2014-09-24       Impact factor: 3.344

Review 5.  Obesity and type 2 diabetes in Sub-Sahara Africa.

Authors:  Jean Claude Mbanya; Felix K Assah; Jude Saji; Emmanuella N Atanga
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

Review 6.  Epilepsy treatment in sub-Saharan Africa: closing the gap.

Authors:  J H Chin
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

7.  Integrated Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: A Retrospective Cohort Study.

Authors:  Martin Muddu; Andrew K Tusubira; Srish K Sharma; Ann R Akiteng; Isaac Ssinabulya; Jeremy I Schwartz
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

Review 8.  Scaling up chronic disease prevention interventions in lower- and middle-income countries.

Authors:  Thomas A Gaziano; Neha Pagidipati
Journal:  Annu Rev Public Health       Date:  2013-01-07       Impact factor: 21.981

Review 9.  25 by 25: Achieving Global Reduction in Cardiovascular Mortality.

Authors:  Sagar Dugani; Thomas A Gaziano
Journal:  Curr Cardiol Rep       Date:  2016-01       Impact factor: 2.931

10.  Predictors of health facility readiness for diabetes service delivery in low- and middle-income countries: The case of Bangladesh.

Authors:  Jacqueline A Seiglie; Edson Serván-Mori; Tahmina Begum; James B Meigs; Deborah J Wexler; Veronika J Wirtz
Journal:  Diabetes Res Clin Pract       Date:  2020-09-04       Impact factor: 5.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.